(326) Nanoparticles-mediated codelivery of cell cycle blockers for the treatment of prostate cancer
Introduction: Genomic alterations in tumor suppressor genes are common in prostate cancers, particularly in castration-resistant prostate cancer (CRPC), making them sensitive to G2/M checkpoint-targeting therapies. This checkpoint is primarily regulated by the ATR/CHK1/WEE1 pathway, highlighting the therapeutic potential of co-inhibition of WEE1 and CHK1. However, its clinical translation is limited by low efficacy and dose-limiting toxicities. Therefore, innovative drug combinations and delivery systems are needed to enhance safety and efficacy, potentially transforming cancer treatment strategies of CRPC.
Learning Objectives:
Understand the mechanism of synergistic action of ADZ1775/SRA737 combination in cancer treatment.
Evaluate factors affecting CD44 targeting by hyaluronic acid (HA)-based nanoparticles in therapies.
Investigate if inhibition COX-2 induction induced by cell cycle blockers can enhance cancer therapy.
